The application of CCExo system was demonstrated in primary cells of patients with chronic myeloid leukemia (CML) harboring the BCR-ABL fusion gene and in a xenograft animal model, where cancer suppression and elimination was induced via plasmid DNA or RNP delivery, thus underlining the CCExo approach as a potential therapeutic option for treatment of CML and other disorders with genetic etiology. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.